Skip to main
BLFS

BioLife Solutions (BLFS) Stock Forecast & Price Target

BioLife Solutions (BLFS) Analyst Ratings

Based on 5 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

BioLife Solutions is expected to continue its strong performance with 18 unique commercial cell & gene therapy products, with potential for regulatory approvals of 8 more products in the next 12 months. Despite a slight decrease in gross margins, the company's adjusted EBITDA increased over 30%, reflecting strong financial health. With a solid cash position of $113.1 million and an anticipated acquisition by Repligen, shares are fairly valued at $31 with a Hold rating. Investment risks include regulatory hurdles, competition, and potential delays or weaknesses in the acquisition process.

Bears say

BioLife Solutions is a life sciences company with a negative outlook due to challenges in the biopreservation market and a recent divestiture of non-core units, leading to lower financial projections. Additionally, the company's acquisition by Repligen may not provide enough value to shareholders and could lead to integration issues. There are also risks within the medical and life science sector, such as reduced R&D budgets, government funding, and regulatory hurdles, that could negatively impact BioLife's revenue.

BioLife Solutions (BLFS) has been analyzed by 5 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioLife Solutions (BLFS) Forecast

Analysts have given BioLife Solutions (BLFS) a Hold based on their latest research and market trends.

According to 5 analysts, BioLife Solutions (BLFS) has a Hold consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioLife Solutions (BLFS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.